$MRSH

Beswick Paul sold $141K of MRSH

Beswick Paul (SVP, Chief Information Officer) sold 713 shares of MARSH & MCLENNAN COMPANIES, INC. (MRSH) at $198.00 ($0.14M total) on 2026-07-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Beswick Paul
Published Jul 31, 2026, 8:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 8:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MRSH
Neutral
high confidence
Mentioned
$MRSH
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRSHNeutralLow
01

Why it matters

The disclosed event is an open-market sale by an officer (SVP, Chief Information Officer) under a pre-arranged Rule 10b5-1 plan; it does not include any new corporate event or guidance.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure generally reduces interpretive weight versus unscheduled selling.

03

What to watch

The article provides only the sale details, not total insider ownership changes across time, and does not indicate whether other insiders or the company also executed buys/sales around the same window.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-31, transaction dated 2026-07-29

Background

The article is an SEC Form 4 insider transaction disclosure for Marsh & McLennan (MRSH).

Company-level read

Ticker impact

$MRSHNeutralHigh confidence
Context

Marsh & McLennan filed an SEC Form 4 showing SVP/CIO Beswick Paul sold 713 shares at $198 on 2026-07-29 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price reaction; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, and it does not disclose new company performance, guidance, or regulatory/contract events.

Market effects

No clear sector read-through; this is company-specific insider selling with no operational or regulatory catalyst.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with executives de-risking ahead of personal liquidity needs, which some traders may still interpret as mild caution.

Key entities

  • Marsh & McLennan Companies, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Beswick Paul

    SVP, Chief Information Officer who sold 713 shares.

Related articles

$MRSHMed

Marsh & McLennan Companies Q2 Earnings Call Highlights

Marsh & McLennan (NYSE:MRSH) reported Q2 results and discussed market conditions on its earnings call. Consulting revenue rose 10% to $2.6B, with adjusted operating income up 11% to $533M. Mercer revenue was $1.6B. Marsh Global Insurance Market Index showed primary commercial rates down 6% in Q2. The company ended with $20.6B debt and $1.7B cash, and expects $5.5B capital deployment in 2026.

$MRSHMed

Marsh (NYSE:MRSH) Exceeds Q2 CY2026 Expectations

Marsh (NYSE:MRSH) reported Q2 CY2026 results. Revenue rose 6.2% year on year to $7.40 billion, exceeding Wall Street’s estimate by 1.8%, and non-GAAP EPS was $2.96, 2.3% above consensus. Adjusted operating margin was 26.9%. Analysts expect revenue growth of 4.2% and full-year EPS to rise from $10.22 to $10.90.

$MRSHMed

MARSH & MCLENNAN COMPANIES, INC. (MRSH): Results of Operations and Financial Condition

MARSH & MCLENNAN COMPANIES, INC. (MRSH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mmc2q2026ex991newsrelease.htm PRESS RELEASE JUNE 30, 2026 Document Marsh 212 345 5000 www.corporate.marsh.com News release Exhibit 99.1 Marsh reports second quarter 2026 results • Revenue Growth of 6%; Underlying Revenue Growth of 5% • GAAP Operating Income Increases 4%

$MRSHHighAI 9/10

Marsh & McLennan Companies (NYSE:MRSH) Stock Price Down 13.1% After Analyst Downgrade

Marsh & McLennan (NYSE:MRSH) fell 13.1% mid-day Wednesday after Piper Sandler cut its price target to $182 from $190 and kept a neutral rating. Shares traded as low as $180.97 and last at $160.70, after closing $185.00; volume rose to 3.04M. The article also cites recent analyst target changes and April 16 quarterly results: $3.29 EPS vs $3.21 consensus on $7.30B revenue.